The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Identifying beneficial subgroups for immunotherapy in BTC using AI tools
Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Korea, highlights the challenges in using immune checkpoint inhibitors (ICI) for biliary tract cancer (BTC) due to their high cost and marginal benefit. He emphasizes the need for biomarkers to better stratify patients who will benefit from ICIs. Artificial intelligence (AI) and machine learning tools are showing promise in identifying subgroups, such as inflamed patients, who demonstrate significant benefit from ICI monotherapy, offering a potential path forward in BTC treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
